495 related articles for article (PubMed ID: 16471901)
1. How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? Mechanistic insights from computational modeling and the implication for rational design of anti-HIV-1 entry inhibitors.
Hamza A; Zhan CG
J Phys Chem B; 2006 Feb; 110(6):2910-7. PubMed ID: 16471901
[TBL] [Abstract][Full Text] [Related]
2. Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: Potential for HIV-1 therapy.
Williamson MP; McCormick TG; Nance CL; Shearer WT
J Allergy Clin Immunol; 2006 Dec; 118(6):1369-74. PubMed ID: 17157668
[TBL] [Abstract][Full Text] [Related]
3. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
Zhao Q; Ma L; Jiang S; Lu H; Liu S; He Y; Strick N; Neamati N; Debnath AK
Virology; 2005 Sep; 339(2):213-25. PubMed ID: 15996703
[TBL] [Abstract][Full Text] [Related]
4. Functional design of potential inhibitors of human immunodeficiency virus (HIV) binding to CD4+ target cells: a molecular model of gp120 predicts ligand binding.
Gabriel JL; Mitchell WM
Drug Des Discov; 1996 Oct; 14(2):103-14. PubMed ID: 9010617
[TBL] [Abstract][Full Text] [Related]
5. Docking and 3D-QSAR studies of BMS-806 analogs as HIV-1 gp120 entry inhibitors.
Teixeira C; Serradji N; Maurel F; Barbault F
Eur J Med Chem; 2009 Sep; 44(9):3524-32. PubMed ID: 19410340
[TBL] [Abstract][Full Text] [Related]
6. A peptidomimetic HIV-entry inhibitor directed against the CD4 binding site of the viral glycoprotein gp120.
Neffe AT; Meyer B
Angew Chem Int Ed Engl; 2004 May; 43(22):2937-40. PubMed ID: 15170309
[No Abstract] [Full Text] [Related]
7. A dynamic target-based pharmacophoric model mapping the CD4 binding site on HIV-1 gp120 to identify new inhibitors of gp120-CD4 protein-protein interactions.
Caporuscio F; Tafi A; González E; Manetti F; Esté JA; Botta M
Bioorg Med Chem Lett; 2009 Nov; 19(21):6087-91. PubMed ID: 19783140
[TBL] [Abstract][Full Text] [Related]
8. A combination of molecular dynamics and docking calculations to explore the binding mode of ADS-J1, a polyanionic compound endowed with anti-HIV-1 activity.
Manetti F; Tintori C; Armand-Ugón M; Clotet-Codina I; Massa S; Ragno R; Esté JA; Botta M
J Chem Inf Model; 2006; 46(3):1344-51. PubMed ID: 16711753
[TBL] [Abstract][Full Text] [Related]
9. Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions.
Biorn AC; Cocklin S; Madani N; Si Z; Ivanovic T; Samanen J; Van Ryk DI; Pantophlet R; Burton DR; Freire E; Sodroski J; Chaiken IM
Biochemistry; 2004 Feb; 43(7):1928-38. PubMed ID: 14967033
[TBL] [Abstract][Full Text] [Related]
10. Docking studies and model development of tea polyphenol proteasome inhibitors: applications to rational drug design.
Smith DM; Daniel KG; Wang Z; Guida WC; Chan TH; Dou QP
Proteins; 2004 Jan; 54(1):58-70. PubMed ID: 14705024
[TBL] [Abstract][Full Text] [Related]
11. Actinohivin, a novel anti-human immunodeficiency virus protein from an actinomycete, inhibits viral entry to cells by binding high-mannose type sugar chains of gp120.
Chiba H; Inokoshi J; Nakashima H; Omura S; Tanaka H
Biochem Biophys Res Commun; 2004 Mar; 316(1):203-10. PubMed ID: 15003531
[TBL] [Abstract][Full Text] [Related]
12. Computational discovery of novel HIV-1 entry inhibitors based on potent and broad neutralizing antibody VRC01.
Andrianov AM; Kashyn IA; Tuzikov AV
J Mol Graph Model; 2015 Sep; 61():262-71. PubMed ID: 26298811
[TBL] [Abstract][Full Text] [Related]
13. Synthetic bivalent CD4-mimetic miniproteins show enhanced anti-HIV activity over the monovalent miniprotein.
Li H; Song H; Heredia A; Le N; Redfield R; Lewis GK; Wang LX
Bioconjug Chem; 2004; 15(4):783-9. PubMed ID: 15264865
[TBL] [Abstract][Full Text] [Related]
14. The antifolate activity of tea catechins.
Navarro-Perán E; Cabezas-Herrera J; García-Cánovas F; Durrant MC; Thorneley RN; Rodríguez-López JN
Cancer Res; 2005 Mar; 65(6):2059-64. PubMed ID: 15781612
[TBL] [Abstract][Full Text] [Related]
15. Molecular modeling on human CCR5 receptors and complex with CD4 antigens and HIV-1 envelope glycoprotein gp120.
Yang J; Liu CQ
Acta Pharmacol Sin; 2000 Jan; 21(1):29-34. PubMed ID: 11263244
[TBL] [Abstract][Full Text] [Related]
16. Atomic insight into the CD4 binding-induced conformational changes in HIV-1 gp120.
Hsu ST; Bonvin AM
Proteins; 2004 May; 55(3):582-93. PubMed ID: 15103622
[TBL] [Abstract][Full Text] [Related]
17. Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120 crystal structures, molecular mimicry, and neutralization breadth.
Huang CC; Stricher F; Martin L; Decker JM; Majeed S; Barthe P; Hendrickson WA; Robinson J; Roumestand C; Sodroski J; Wyatt R; Shaw GM; Vita C; Kwong PD
Structure; 2005 May; 13(5):755-68. PubMed ID: 15893666
[TBL] [Abstract][Full Text] [Related]
18. Is the V3 loop involved in HIV binding to CD4?
Dettin M; Ferranti P; Scarinci C; Picariello G; Di Bello C
Biochemistry; 2003 Aug; 42(30):9007-12. PubMed ID: 12885233
[TBL] [Abstract][Full Text] [Related]
19. Methylation of green tea polyphenols affects their binding to and inhibitory poses of the proteasome beta5 subunit.
Daniel KG; Landis-Piwowar KR; Chen D; Wan SB; Chan TH; Dou QP
Int J Mol Med; 2006 Oct; 18(4):625-32. PubMed ID: 16964415
[TBL] [Abstract][Full Text] [Related]
20. Epigallocatechin gallate, the main component of tea polyphenol, binds to CD4 and interferes with gp120 binding.
Kawai K; Tsuno NH; Kitayama J; Okaji Y; Yazawa K; Asakage M; Hori N; Watanabe T; Takahashi K; Nagawa H
J Allergy Clin Immunol; 2003 Nov; 112(5):951-7. PubMed ID: 14610487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
